Trials / Completed
CompletedNCT00853242
Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using Genz-644470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 349 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in hyperphosphatemic chronic kidney disease participants on hemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | |
| DRUG | Genz-644470 | |
| DRUG | Sevelamer carbonate |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2009-03-02
- Last updated
- 2015-05-01
- Results posted
- 2015-05-01
Locations
53 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT00853242. Inclusion in this directory is not an endorsement.